AOBiome ^Company

AOBiome is a Boston-based biotech company focused on transforming human health through products that restore ammonia-oxidizing bacteria (AOB). The company is developing a novel therapeutic class to improve skin health, hypertension, and other systemic conditions. AOBiome has completed six Phase 2 clinical programs and multiple preclinical programs. Over 1,000 patients have been enrolled in clinical trials since 2016. In 2021, the company is enrolling 600 patients in a double-blind placebo-controlled trial to treat adults with pruritus associated with atopic dermatitis in support of its lead program